646 results about "Tumor therapy" patented technology

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention discloses application of a target protein circPIAS1-108aa inhibitor combined with oxaliplatin in preparation of a medicine synergistic composition for treating cancers, the specific action mechanism of circPIAS1-108aa in colon cancer treatment is found for the first time, and further research shows that by using siRNA to knock down circPIAS1-108aa, colon cancer cell proliferation can be remarkably inhibited, and the effect of treating the colon cancer can be achieved. Furthermore, the target spot protein circPIAS1-108aa inhibitor can be used for enhancing the treatment effect of the oxaliplatin. Therefore, when the circPIAS1-108aa expression is inhibited in a targeted manner and the oxaliplatin is combined for use, the circPIAS1-108aa can be obviously used for preventing and treating cancers, the dosage and toxic and side effects of the oxaliplatin are reduced, and a new synergistic strategy is provided for tumor treatment.

The invention discloses a drug delivery system based on branched chain nucleic acid as well as a preparation method and application of the drug delivery system. The drug delivery system comprises a multivalent nucleic acid framework, a nucleic acid-small molecule coupling drug and a nucleic acid-polypeptide coupling drug, a nucleic acid nanostructure is formed through base complementary pairing assembly, and the nucleic acid-small molecule coupling drug comprises first nucleic acid and an E3 ubiquitin ligase ligand coupled with the first nucleic acid; the nucleic acid-polypeptide coupling drug comprises a second nucleic acid and a cell penetrating peptide coupled with the second nucleic acid. The drug delivery system disclosed by the invention can respond to a tumor microenvironment, so that cell penetrating peptides are activated, tumor penetrating and cytoplasm delivery capacities are enhanced, the aim of efficiently degrading tumor-related target proteins is fulfilled by combining a multivalent effect, and a remarkable tumor treatment effect is achieved; in addition, the preparation method is simple and easy to implement, has universality and high production efficiency, and is expected to be applied to treatment of various tumors.

The invention discloses a longitudinal CT image-assisted rectal cancer neoadjuvant radiotherapy and chemotherapy treatment reaction evaluation device, which comprises a focus area segmentation module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module and a rectum focus area detection module, obtaining a standardized three-dimensional tumor area; a feature fusion module extracts deep learning features of a focus area after segmentation at two time points before neoadjuvant radiotherapy and chemotherapy and before an operation from the three-dimensional tumor area, and performs weighted fusion on the deep learning features at the two time points through a dynamic attention weight layer to obtain longitudinal comprehensive features representing tumor treatment response changes; and the prediction module fuses the longitudinal comprehensive characteristics and clinical baseline data to construct a multi-modal prediction model, and outputs a treatment response prediction result of the rectal cancer patient on neoadjuvant chemoradiotherapy, so that the prediction accuracy of pathological complete remission of the rectal cancer patient can be improved, and the prognosis of the patient and the utilization efficiency of medical resources can be improved.

The invention provides application of a small molecule drug for promoting triple negative breast cancer ferroptosis, and belongs to the technical field of tumor treatment. The inducer can effectively kill triple negative breast cancer cells by triggering a ferroptosis pathway. The invention discovers that the inhibitor can reduce the expression of a key protein RPTOR by inhibiting the activity of an mTORCl compound, thereby weakening the anti-oxidation defense capability of triple negative breast cancer cells, greatly enhancing the accumulation of lipid peroxide, and further strongly inducing the occurrence of ferroptosis. The component of the culture medium is a DMEM (Dulbecco Modified Eagle Medium) containing 10% of fetal calf serum, and 2 [mu] M of Torinl is added at the same time. The invention discloses a new target spot of ferroptosis of the triple-negative breast cancer, and provides a new thought for treatment of the triple-negative breast cancer.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention discloses application of a tripterygium wilfordii exosome in preparation of an anti-cervical cancer medicine and a tumor angiogenesis inhibiting medicine, and relates to the field of biological medicine. The medicinal plant exosome derived from tripterygium wilfordii is successfully separated, and it is proved that the medicinal plant exosome can regulate related pathways through delivery of functional nucleic acid molecules to inhibit proliferation and migration of cervical cancer cells and promote active oxygen related apoptosis so as to be used for tumor treatment. The tripterygium wilfordii exosome can further act on vascular endothelial cells in a tumor microenvironment, the migration function of Hela cells is inhibited, and then the effect of resisting cell proliferation in the tumor microenvironment is achieved. The tripterygium wilfordii exosome has the advantages of being simple in preparation method, remarkable in tumor growth resistance and tumor cell migration inhibition effect, good in biocompatibility, high in delivery efficiency and the like, and can be used as a novel nano-drug for tumor treatment.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

The invention belongs to the technical field of tumor treatment, and particularly relates to a metal polyphenol network coated drug-loaded mesoporous organic silicon nanoparticle and a preparation method and application thereof.The mesoporous organic silicon nanoparticle (MON) is prepared through a micelle / precursor co-template assembly method, then amination modification, carboxylation modification and drug co-loading are further conducted on the mesoporous organic silicon nanoparticle (MON), and the metal polyphenol network coated drug-loaded mesoporous organic silicon nanoparticle is obtained. The DQMCTH nano-particles are prepared through the steps that DQMCTH nano-particles are taken as a raw material, a copper salt solution and a tannic acid (TA) solution are added and mixed, then a coordination complexation reaction is conducted, hyaluronic acid (HA) is added for modification, and the DQMCTH nano-particles obtained through the method are in a sphere-like shape, regular in shape, uniform in distribution and free of obvious dendritic branches and central radial pore channels. The polypeptide is effectively protected by MPN and is subjected to HA targeted modification; more importantly, the DQMCTH nanoparticles prepared by the method disclosed by the invention show pH / GSH / HAase triple sensitive drug release, and cell and animal experiment results show that the DQMCTH nanoparticles prepared by the method disclosed by the invention have relatively high anti-tumor activity on a drug-resistant breast cancer model.

The invention relates to the technical field of tumor treatment, in particular to a tumor patient symptom group collaborative management system, comprising a data acquisition module used for acquiring patient information and environment information through an intelligent device; the feature extraction module is used for data acquisition of the data acquisition module, and the feature extraction module performs feature extraction on the patient information and the environment information to obtain time domain features, frequency domain features and nonlinear features corresponding to symptoms; the evaluation platform identifies the core symptom group of the patient according to the time domain feature, the frequency domain feature and the nonlinear feature and calculates a total load index; the evaluation platform also performs symptom deterioration early warning; the collaboration platform is used for storing a disease knowledge base and identifying and obtaining a corresponding multi-mode intervention scheme according to the condition of a patient; and the patient terminal is used for pushing the multi-mode intervention scheme to the patient. According to the invention, the symptom group of the tumor patient can be managed as a whole, a personalized and real-time intervention scheme is provided for the patient, and the treatment effect is improved.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The application discloses a breast-conserving surgery perforator flap intelligent navigation system and method based on CT three-dimensional blood vessel reconstruction and AI dynamic blood flow analysis, and comprises an image processing module. The image processing module generates a perforator blood vessel three-dimensional model with an accuracy of plus or minus 0.1 mm based on high-resolution CT thin-layer scanning data with a layer thickness of less than or equal to 0.625 mm through Mimics software. The application significantly improves the postoperative outcome of patients through multidimensional technology cooperation. In terms of complication control, the incidence of complications in the donor area is reduced from 22% in the traditional method to 3% (a reduction of 86%), and the expansion of trauma caused by perforator variation is avoided. In terms of aesthetic effect, for the breast-conserving surgery of medial quadrant breast cancer, the lateral thoracic artery perforator flap (LTAP) is combined with AI volume compensation. After the surgery, the postoperative breast upper pole depression rate is reduced from 35% to 5%, the BREAST-Q score of the patient is increased from 68 to 89, the requirements of 'tumor radical treatment' and 'functional aesthetics' are fully considered, the postoperative life quality of the patient is greatly improved, and the humanistic concept of modern tumor treatment is met.

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

A transducer device for delivering a tumor therapy electric field to a body of a subject, the transducer device comprising: a substrate; and an array of at least one electrode disposed on the substrate, the array configured to be positioned over the subject's body, the face of the array facing the subject's body; wherein the transducer device has a substantially non-planar shape, and wherein the transducer device is substantially shaped as a truncated elliptical paraboloid, a truncated oblique cone, or a truncated cone, and a substantially circular opening is formed by an opening at a truncated portion of the truncated elliptical paraboloid, the truncated oblique cone, or the truncated cone.

This invention relates to a pharmaceutical composition for tumor treatment and its application. Specifically, this invention relates to a composition containing a fluorouracil drug and pyrimidine nucleosides and their derivatives. Fluorouracil drugs and pyrimidine nucleotides and their derivatives have a synergistic antitumor effect; combined use can reduce the concentration of single drugs and achieve better antitumor efficacy, while reducing toxic side effects.

The invention belongs to the field of traditional Chinese medicines, and provides astragalus membranaceus and jujube heart-protecting granules as well as a preparation method and application thereof, and the astragalus membranaceus and jujube heart-protecting granules are prepared from the following medicinal materials: raw astragalus membranaceus, codonopsis pilosula, semen ziziphi spinosae, salvia miltiorrhiza, angelica sinensis, ligusticum wallichii and cassia twig. The astragalus membranaceus and jujube heart-protecting granules are convenient to carry and take, experiments prove that the astragalus membranaceus and jujube heart-protecting granules are helpful for preventing or treating cardiotoxicity of targeted drugs and / or immune examination inhibitors, and a new solution is provided for expanding the application of astragalus membranaceus and jujube heart-protecting prescriptions and solving the problem of cardiotoxicity of traditional Chinese medicines for tumor treatment.

The present application relates to the technical field of medical apparatus and instruments, in particular to a radiotherapy device with protection function for tumor treatment. The radiotherapy device comprises a lifting platform, a first moving platform is slidably arranged on the lifting platform, a second moving platform is slidably connected to the first moving platform, a first electric sliding rail is arranged on the second moving platform, an electric sliding block on the first electric sliding rail is provided with a first electric rotating shaft, a second electric sliding rail is fixedly connected to the first electric rotating shaft, an electric sliding block on the second electric rotating shaft is provided with a second electric rotating shaft, a third electric sliding rail is fixedly connected to the second electric rotating shaft, an electric sliding block on the third electric sliding rail is rotatably connected to a fixing frame, the fixing frame is provided with a third electric rotating shaft, the fixing frame is rotatably connected to a pressing frame, and the third electric rotating shaft is fixedly connected to a supporting frame. The body film is clamped by the pressing frame and the supporting frame, so that the body film is stably attached to the skin of the patient, and the support of the body film is pressed after the body film contacts the second moving platform, so that the position of the body film is ensured not to change.

A computer-implemented method for selecting at least one transducer location for delivering tumor treating fields to a subject, the method including: obtaining a three-dimensional model which includes voxels associated with image data of the subject; computing a discretization of the model to obtain a discretized model; computing boundary conditions for the discretized model; computing a matrix A is based on the discretized model and a vector b based on the boundary conditions for each respective transducer location; computing a vector φ using the matrix A and the vector b for each transducer location, wherein the vector φ is computed by computationally solving an equation Aφ=b, wherein each vector φ represents electrical potentials for the discretized model for each respective transducer location; and selecting one or more transducer locations for delivering tumor treating fields to the subject based on the vectors φ.

The invention relates to an up-regulation Nuak1 immune cell and application thereof, and particularly provides an over-expression Nuak1 immune cell and application thereof in preparation of drugs for treating diseases. Specifically, up-regulation of the Nuak1 in immune cells can significantly improve the toxicity, proliferative activity and cytokine or GZMB secretion ability of the immune cells, and further has the effect of enhancing tumor treatment.

The application discloses a recombinant oncolytic virus targeting CD317 gene and application thereof in anti-tumor, and belongs to the technical field of tumor treatment. The recombinant oncolytic virus comprises a CD317 inhibitor and an oncolytic virus, and is formed by integrating the CD317 inhibitor into the oncolytic virus genome. The CD317 inhibitor is a substance capable of inhibiting CD317 gene expression or targeting degradation of CD317 protein function, and is selected from shRNA or siRNA targeting CD317. The application develops the oncolytic virus targeting knockdown of CD317 expression, inhibits tumor cell proliferation by reducing CD317 expression of tumor cells, reduces PD-L1 expression so as to break the immune escape mechanism, simultaneously enhances the killing sensitivity of tumor cells to CD8+ T cells, forms a synergistic effect with the oncolysis of the oncolytic virus, and the recombinant oncolytic virus has stronger in-vivo anti-tumor activity, thereby providing a new potential scheme for CD317-driven tumor treatment.

Provided are compositions for use in treating a subject having a small cell lung cancer (SCLC) - derived tumor having a high tumor mutational burden (TMB) status.SOLUTION: Provided are methods of treating a subject having an SCLC-derived tumor having a TMB status, comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. Also provided are methods of identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody, comprising determining the TMB status in a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. TMB status can be determined by sequencing nucleic acids in the tumor and identifying genomic alterations, e.g., somatic non-synonymous mutations, in the sequenced nucleic acids.SELECTED DRAWING: None

Described herein are devices for applying an alternating electric field to a living subject or an in vitro medium at a frequency between 100 kHz and 500 kHz. Also described herein are methods of using the described devices for applying an AC electric field to a target region comprising rapidly dividing cells, e.g., cells associated with a variety of disorders or conditions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

Compositions, systems, and methods are disclosed for reducing the viability of cancer cells and treating cancer, as well as preventing an increase in volume of a tumor present in the body of a living subject. The systems and methods involve applying an alternating field while administering at least one composition that increases the expression of MHC class I molecules in cancer cells.

The application discloses an inhibitor for inhibiting KRAS phase separation to play an anti-tumor role and application, and relates to the fields of tumor molecular biology and targeted therapy.The application aims at solving the problems of limited effect, strong drug resistance and limited application range of KRAS tumor treatment methods, and the inhibitor is a statin.The KRAS protein can form a liquid condensate in cells, and the application discloses the mechanism of the KRAS protein in promoting KRAS protein processing, transportation and downstream signal activation, and further provides a technical scheme for inhibiting tumor growth and enhancing the therapeutic effect of a KRAS inhibitor by inhibiting the formation of KRAS condensates, so as to provide a new target and intervention approach for tumor treatment.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The present invention provides a bispecific antibody comprising a first portion targeting PD-L1 and a second portion targeting IL-1, wherein the first portion comprises an anti-PD-L1 antibody or its antigen-binding fragment, and the second portion comprises the extracellular binding domain of the IL-1 receptor (IL-1R) or a variant thereof, or an anti-IL-1β antibody or its antigen-binding fragment. The invention also provides the use of the bispecific antibody in the treatment of tumors.

The invention provides a construction method and application of a humanized MECP2 gene mouse model, and relates to the field of gene engineering. The model animal with the humanized hMECP2 gene is successfully prepared, the humanized hMECP2 protein can be normally expressed in the body of the model, and the model can be used for MECP2 gene function research and screening and evaluation of human MECP2 targeted drugs and therapies. The animal model prepared by the invention can be used for rapidly establishing more different MECP2 mutation humanized disease mouse models, and is applied to drug screening, drug effect research, related nervous system disease and tumor treatment and the like aiming at human MECP2 target sites, so that the research and development process of new drugs is accelerated, the time and the cost are saved, and the drug development risk is reduced. And a powerful tool is provided for researching the functions of the MECP2 protein and screening drugs.

The invention discloses a compound with a multi-element heterocyclic structure as well as a pharmaceutical composition and application of the compound. The invention provides a compound with a multi-heterocyclic structure as shown in a formula I, pharmaceutically acceptable salts thereof, solvates thereof, solvates of the pharmaceutically acceptable salts thereof, crystal forms thereof, stereoisomers thereof, tautomers thereof or isotope compounds thereof. As an inhibitor, the compound with the multi-element heterocyclic structure can meet the requirements of tumor treatment and is beneficial to reducing adverse reactions caused by PARP-2 inhibition.

The invention discloses a preparation method and application of polypeptide hydrogel loaded with modified CAR-T cells and CXCL9, and creatively discovers that the combination of the modified CAR-T cells and the CXCL9 has a remarkable synergistic effect on treatment of melanoma for the first time. According to the invention, efficient enrichment of CAR-T cells at a focus part is realized through the hydrogel delivery system, the local curative effect is improved, in addition, the introduction of CXCL9 further enhances the tumor infiltration capability and the treatment effect of the CAR-T cells, a brand new treatment scheme is provided for tumor treatment, and the clinical application prospect is wide.